O. H. Aina, T. C. Sroka, M. L. Chen, and K. S. Lam, Therapeutic cancer targeting peptides, Peptide Science: Original Research on Biomolecules, vol.66, issue.3, pp.184-199, 2002.

N. Akyüz, G. S. Boehden, S. Süsse, A. Rimek, U. Preuss et al.,

H. Wiesmüller and L. , DNA substrate dependence of p53-mediated regulation of double-strand break repair, Molecular and cellular biology, vol.22, issue.17, pp.6306-6317, 2002.

T. M. Allen, Ligand-targeted therapeutics in anticancer therapy, Nature Reviews Cancer, vol.2, issue.10, p.750, 2002.

J. Bartek and J. Lukas, Pathways governing G1/S transition and their response to DNA damage, FEBS letters, vol.490, issue.3, pp.117-122, 2001.

S. J. Baker, S. Markowitz, E. R. Fearon, J. K. Willson, and B. Vogelstein, Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, issue.4971, pp.912-915, 1990.

J. Bartek and J. Lukas, DNA damage checkpoints: from initiation to recovery or adaptation. Current opinion in cell biology, vol.19, pp.238-245, 2007.

S. B. Baylin, DNA methylation and gene silencing in cancer, Nature Reviews Clinical Oncology, vol.2, issue.S1, p.4, 2005.

S. B. Baylin and J. G. Herman, DNA hypermethylation in tumorigenesis: epigenetics joins genetics, Trends Genet, vol.16, p.168174, 2000.

C. Borghouts, C. Kunz, and B. Groner, Current strategies for the development of peptidebased anticancer therapeutics, vol.11, pp.713-726, 2005.

J. C. Bourdon, K. Fernandes, F. Murray-zmijewski, G. Liu, A. Diot et al., p53 isoforms can regulate p53 transcriptional activity, Genes & development, vol.19, issue.18, pp.2122-2137, 2005.

S. W. Chi, S. H. Lee, D. H. Kim, M. J. Ahn, J. S. Kim et al., Structural details on mdm2-p53 interaction, Journal of Biological Chemistry, vol.280, issue.46, pp.38795-38802, 2005.

J. E. Chipuk, T. Kuwana, L. Bouchier-hayes, N. M. Droin, D. D. Newmeyer et al., Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis, Science, issue.5660, pp.1010-1014, 2004.

C. J. Dehart, J. S. Chahal, S. J. Flint, and D. H. Perlman, Extensive post-translational modication of active and inactivated forms of endogenous p53, Mol Cell Proteomics, p.24056736, 2013.

J. L. Díaz-gómez, F. Castorena-torres, R. E. Preciado-ortiz, and S. Garcíalara, Anti-Cancer Activity of Maize Bioactive Peptides, Frontiers in chemistry, vol.5, p.44, 2017.

K. Ding, Y. Lu, Z. Nikolovska-coleska, G. Wang, S. Qiu et al.,

P. P. Roller, Structure-based design of spiro-oxindoles as potent, specic small-molecule inhibitors of the MDM2¡ p53 interaction, Journal of medicinal chemistry, vol.49, issue.12, pp.3432-3435, 2006.

E. Gasteiger, C. Hoogland, A. Gattiker, M. R. Wilkins, R. D. Appel et al., Protein identication and analysis tools on the ExPASy server, The proteomics protocols handbook, pp.571-607, 2005.

N. P. Gomes and J. M. Espinosa, Dierential regulation of p53 target genes: it's (core promoter) elementary, Genes & development, vol.24, issue.2, pp.111-114, 2010.

D. W. Goodrich and W. H. Lee, Molecular characterization of the retinoblastoma susceptibility gene, Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, vol.1155, issue.1, pp.43-61, 1993.

C. Gros, J. Fahy, L. Halby, I. Dufau, A. Erdmann et al., DNA methylation inhibitors in cancer: recent and future approaches, Biochimie, vol.94, issue.11, pp.2280-2296, 2012.

T. D. Halazonetis, V. G. Gorgoulis, and J. Bartek, An oncogene-induced DNA damage model for cancer development, science, issue.5868, pp.1352-1355, 2008.

J. W. Harper, S. J. Elledge, K. Keyomarsi, B. Dynlacht, L. H. Tsai et al., Inhibition of cyclin-dependent kinases by p21, Molecular biology of the cell, vol.6, issue.4, pp.387-400, 1995.

G. He, Z. H. Siddik, Z. Huang, R. Wang, J. Koomen et al., Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities, Oncogene, vol.24, issue.18, p.2929, 2005.

D. Hoeller and I. Dikic, Targeting the ubiquitin system in cancer therapy, Nature, vol.458, issue.7237, p.438, 2009.

B. Hong, P. J. Van-den-heuvel, V. Prabhu, S. Zhang, and W. El-deiry, Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities, 25. International Human Genome Sequencing Consortium, vol.15, issue.1, p.860, 2001.

N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L. G. Verhoef et al.,

G. Selivanova, Small molecule RITA binds to p53, blocks p53HDM2 interaction and activates p53 function in tumors, Nature medicine, vol.10, issue.12, p.1321, 2004.

C. A. Joazeiro, Ribosomal stalling during translation: providing substrates for ribosome-associated protein quality control. Annual review of cell and developmental biology, vol.33, pp.343-368, 2017.

P. A. Jones, Cancer. Death and methylation, Nature, vol.409, issue.6817, pp.141-143, 2001.
URL : https://hal.archives-ouvertes.fr/hal-00868358

M. P. Khoury and J. C. Bourdon, The isoforms of the p53 protein. Cold Spring Harbor perspectives in biology, vol.2, p.927, 2010.

J. P. Kruse and W. Gu, Modes of p53 regulation, Cell, vol.137, issue.4, pp.609-622, 2009.

M. Lübbert, DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action, Current topics in microbiology and immunology, vol.249, pp.135-164, 2000.

M. Male²evi¢, M. Schumann, G. Jahreis, G. Fischer, and C. Lücke, , 2012.

, Design of Cyclic Peptides Featuring Proline Predominantly in the cis Conformation under Physiological Conditions, ChemBioChem, vol.13, issue.14, pp.2122-2127

M. Malumbres and M. Barbacid, Milestones in cell division: to cycle or not to cycle: a critical decision in cancer, Nature Reviews Cancer, vol.1, issue.3, p.222, 2001.

O. W. Mcbride, D. Merry, and D. Givol, The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13), Proceedings of the National Academy of Sciences, vol.83, pp.130-134, 1986.

S. Melnikov, J. Mailliot, L. Rigger, S. Neuner, B. S. Shin et al.,

M. Yusupov, Molecular insights into protein synthesis with proline residues, EMBO reports, p.201642943, 2016.

D. Michael and M. Oren, The p53Mdm2 module and the ubiquitin system, Seminars in cancer biology, vol.13, pp.49-58, 2003.

T. B. Miranda and P. A. Jones, DNA methylation: the nuts and bolts of repression, Journal of cellular physiology, vol.213, issue.2, pp.384-390, 2007.

P. A. Muller and K. H. Vousden, p53 mutations in cancer, Nature cell biology, vol.15, issue.1, 2013.

F. Murray-zmijewski, D. P. Lane, and J. C. Bourdon, p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell dierentiation and response to stress, Cell death and dierentiation, vol.13, issue.6, p.962, 2006.

S. Nag, X. Zhang, K. S. Srivenugopal, M. H. Wang, W. Wang et al., Targeting MDM2-p53 interaction for cancer therapy: are we there yet, Current medicinal chemistry, vol.21, issue.5, pp.553-574, 2014.

M. Oren, Decision making by p53: life, death and cancer. Cell death and dierentiation, vol.10, p.431, 2003.

G. P. Pfeifer and A. Besaratinia, Mutational spectra of human cancer, Human genetics, vol.125, issue.5-6, pp.493-506, 2009.

I. P. Pogribny, M. Pogribna, J. K. Christman, and S. J. James, , 2000.

, Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis, Cancer research, vol.60, issue.3, pp.588-594

M. E. Re, K. Hariharan, and G. Braslawsky, Future of monoclonal antibodies in the treatment of hematologic malignancies, Cancer Control, vol.9, pp.152-166, 2002.

D. Reisman, Transcriptional Activation of the p53 Tumor Suppressor Gene Provides a Rapid Protective Mechanism against DNA Damage during S-phase of the Cell Cycle, J Leuk (Los Angel), vol.1, p.102, 2013.

C. Reverdy, S. Conrath, R. Lopez, C. Planquette, C. Atmanene et al.,

F. Colland, Discovery of specic inhibitors of human USP7/HAUSP deubiquitinating enzyme, Chemistry & biology, vol.19, issue.4, pp.467-477, 2012.

J. Sage, G. J. Mulligan, L. D. Attardi, A. Miller, S. Chen et al.,

T. Jacks, Targeted disruption of the three Rb-related genes leads to loss of G1 control and immortalization, Genes & development, vol.14, issue.23, pp.3037-3050, 2000.

Y. Shen, S. Zhang, X. Huang, K. Chen, J. Shen et al., Involvement of p53 mutation and mismatch repair proteins dysregulation in NNK-induced malignant transformation of human bronchial epithelial cells, 2014.

M. Schroeder and M. J. Mass, CpG Methylation Inactivates the Transcriptional Activity of the Promoter of the Humanp53Tumor Suppressor Gene, Biochemical and biophysical research communications, vol.235, issue.2, pp.403-406, 1997.

M. S. Soengas, Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition, Science, vol.284, p.159, 1999.

M. S. Soengas, P. Capodieci, D. Polsky, J. Mora, M. Esteller et al., Inactivation of the apoptosis eector Apaf-1 in malignant melanoma, Nature, vol.409, issue.6817, p.207, 2001.

N. Y. Storer and L. I. Zon, Zebrash models of p53 functions. Cold Spring Harbor perspectives in biology, 1123.

J. Thundimadathil, Cancer treatment using peptides: current therapies and future prospects, Journal of amino acids, 2012.

J. Thundimadathil and A. Gangakhedkar, Improving stability of peptide drugs through chemical modications, Oligos and Peptides, vol.32, pp.35-38, 2014.

V. Tsuber, Y. Kadamov, L. Brautigam, U. W. Berglund, and T. Helleday, Mutations in Cancer Cause Gain of Cysteine, Histidine, and Tryptophan at the Expense of a Net Loss of Arginine on the Proteome Level, Biomolecules, vol.7, issue.3, p.49, 2017.

L. T. Vassilev, MDM2 inhibitors for cancer therapy, Trends in molecular medicine, vol.13, issue.1, pp.23-31, 2007.

B. Vogelstein and K. W. Kinzler, Cancer genes and the pathways they control, Nature medicine, vol.10, issue.8, p.789, 2004.

B. Vogelstein, D. Lane, and A. J. Levine, Surfing the p53 network, Nature, vol.408, issue.6810, p.307, 2000.

K. H. Vousden and D. P. Lane, p53 in health and disease, Nature reviews Molecular cell biology, vol.8, issue.4, p.275, 2007.

Y. F. Xiao, M. M. Jie, B. S. Li, C. J. Hu, R. Xie et al., Peptide-based treatment: a promising cancer therapy, Journal of immunology research, 2015.

S. Wang, Y. Zhao, D. Bernard, A. Aguilar, and S. Kumar, Targeting the MDM2-p53 protein-protein interaction for new cancer therapeutics, Proteinprotein interactions, pp.57-79, 2012.

X. X. Zhang, H. S. Eden, and X. Chen, Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates, Journal of controlled release, vol.159, issue.1, pp.2-13, 2012.

C. Zhou, J. Hu, H. Ma, A. E. Yagoub, X. Yu et al., Antioxidant peptides from corn gluten meal: orthogonal design evaluation, Food Chem, vol.187, 2015.

S. Zitzmann, V. Ehemann, and M. Schwab, Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo, Cancer research, vol.62, issue.18, pp.5139-5143, 2002.